icos corporation trademark icos american biotechnology company largest biotechnology company us state washington sold eli lilly company founded david blech isaac blech robert nowinski george rathmann pioneer industry chief executive officer ceo cofounder icos focused development drugs treat inflammatory disorders history company conducted clinical trials twelve drugs three reached last phase clinical trials icos also manufactured antibodies biotechnology companies icos best known development tadalafil cialis drug used treat erectile dysfunction drug discovered glaxosmithkline developed icos manufactured marketed partnership eli lilly boosted unique advertising campaign led grey worldwide agency sales cialis allowed icos become profitable cialis drug developed company leukarrest drug treat shock pafase developed sepsis tested phase iii clinical trials testing discontinued unpromising results trials eli lilly acquired icos january icoss workers laid soon cmc biologics danish contract manufacturer bought remnants icos retained remaining icos founded george rathmann robert nowinski christopher henney previously started another biotechnology company rathmann created amgen nowinski launched genetic systems later sold bristolmyers squibb henney cofounded immunex later sold icos formed goal developing new drugs treat underlying causes inflammatory diseases halt disease process early name icos comes icosahedron polyhedron shape many chosen founders originally thought retroviruses might involved founders raised million july many investors including bill gates time largest shareholder company initially temporary offices downtown seattle moved bothell september icos went public june raising george rathmann seen guiding father icos left company february replaced ceo chairman paul clark former executive abbott former icos manager named shortsighted leadership clark factor failure company develop successful drugs apart sold cialis initially codenamed tadalafil drug prescribed erectile dysfunction ed approved pulmonary arterial hypertension pah phosphodiesterase type inhibitor similar function addition ed pah tadalafil undergone clinical trials treatment benign prostatic hyperplasia female sexual tadalafil initially formulated glaxo wellcome glaxosmithkline new drug development partnership glaxo icos began august drug originally researched treatment cardiovascular diseases hypertension focus quickly shifted ed success another inhibitor sildenafil viagra developed icos began research tadalafil clinical trials started two years glaxo let partnership icos lapse including companys share profits resulting drugs drugs development glaxos core icos formed joint venture indianapolisbased eli lilly lilly icos llc develop commercialize tadalafil release cialis united states delayed april food drug administration fda recommended icos perform studies improve labelling address manufacturing cialis approved europe november united states year drug approved oncedaily use ed europe june united states january cialis generated million leading icos post firstever quarterly profit may tadalafil sold adcirca united therapeutics approved united states treatment pulmonary arterial hypertension based data pivotal study begun sale icos eli pfizer lilly icos filed many lawsuits various countries cialis viagra pfizer given broad patent inhibitors britain lilly icos filed complaint london court september patent overturned november grounds pfizers patent based information already public domain patent united states pfizer filed suit lilly icos soon receiving broad us patent inhibitors october united states patent trademark office ordered reexamination patent britain examiner found inhibitors new invention pfizer voiding canada pfizer moved block sales cialis five months approved arguing could consumer backlash pfizer cialis pulled market months later result ongoing patent federal judge refused saying could imagine demonstrations street storming barricades one impotence medicine made may fda began investigating reports sudden blindness users sildenafil fda said received reports condition permanent blindness one eye known nonarteritic anterior ischemic optic neuropathy users sildenafil users tadalafil vardenafil lilly icos voluntarily amended cialis label warn fda criticized handling matter fda safety officer commented unusual reports blindness months journal article published united states senator chuck grassley wrote letter fda detailing criticism saying fdas office new drugs ond taken action despite onds knowledge blindness risks since january general agreement among fda staff last spring label grassleys letter also suggested pfizer resisted adding blindness warning viagras july fda said viagra levitra cialis labels would carry warnings risk sudden blindness though unclear whether drugs actually causing lilly icos hired grey worldwide agency new york part grey global group run cialis advertising cialis advertisements described gentler warmer relaxed feel rivals reflect longer duration tadalafil halflife hours compared sildenafil vardenafil iconic themes cialis advertisements include couples bathtubs slogan moment right cialis advertisements unique among ed drugs went beyond describing ed mentioning drugs result cialis advertisements also first describe side effects fda requires advertisements support specific brand name mention side effects ads levitra viagra mention brand name drug therefore circumventing fda one first advertisements cialis aired super bowl lilly icos paid million oneminute weeks game fda required possible side effects including priapism listed although many parents objected ad aired super bowl janet jacksons halftime wardrobe malfunction overshadowed january physician added advertisements describe side effects onscreen icos began running advertisements percent audience made adults effectively ending super bowl lilly icos pfizer glaxosmithkline spent combined million advertise cialis viagra levitra icos developed several drugs whose purpose disrupt process inflammation research program focused underlying causes inflammation rather specific compounds developed icos tested clinical trials areas sepsis multiple sclerosis ischemic stroke heart attack pancreatitis pulmonary arterial hypertension chronic obstructive pulmonary disease interstitial cystitis psoriasis hemorrhagic shock sexual dysfunction benign prostatic hyperplasia rheumatoid arthritis emphysema chronic bronchitis acute respiratory distress syndrome rovelizumab tradenamed leukarrest also known developed treat patients hemorrhagic shock caused massive blood drug monoclonal antibody inhibits recruitment white blood cells site testing patients given drug leukarrest administered within four hours injury informed consent patients often unconscious relatives reached give june icos many medical centers asked fda waive consent requirements situations patient high risk dying relatives could medical ethicists opposed waiving fda approved proposal august five medical development leukarrest halted april interim data phase iii clinical trials meet icoss significantly reducing chance multiple organ failure reducing death rate shock leukarrest also tested unsuccessfully treatment heart attack multiple sclerosis pafase also known rpafah developed treat severe pafase recombinant form plateletactivating factor acetylhydrolase pafah also known lipoproteinassociated phospholipase enzyme made naturally macrophages found human pafah inactivates plateletactivating factor phospholipid plays role inflammation seen enzyme discovered graduate student diana stafforini researchers steve prescott guy zimmerman tom mcintyre university gene codes pafase discovered early trials sepsis showed drug reduced death rate days patients less likely develop severe respiratory icos also tested pafase acute respiratory distress syndrome phase ii trials ards pafase reduced death rate days reduced chance lungs patient would however icos halted development december interim data phase iii trials sepsis showed drug help patients scientists northwestern university later studied pafase necrotizing ongoing research enzyme atherosclerosis university june icos texas biotechnology formed partnership research endothelin receptor antagonists use areas pulmonary hypertension chronic heart two drugs sitaxentan sodium also spelled sitaxsentan tested clinical trials sitaxentan designed treat pulmonary arterial hypertension designed treat cardiovascular diseases april icos sold part partnership including share sitaxentan texas biotechnology million closing another million within sitaxentan sodium later approved europe canada australia marketed brand name thelin voluntarily withdrawn market worldwide due concerns irreversible liver damage icos tested many drugs approved icos manufactured many antibodies various companies august company partnered seattle genetics manufacture component top experimental antibody drug november icos signed production agreement gpc biotech manufacture class gpcs antibodies targeted bcell january icos signed agreement eos icos would produce eoss promising monoclonal antibody candidate eos would nonexclusive rights icoss enhanced mammalian protein production eoss antibody inhibited angiogenesis formation new blood vessels researched treatment solid october icos partnered protein design labs manufacture icoss experimental drugs failed clinical trials eli lilly prime position purchase company october eli lilly announced reached terms acquire icos billion receiving pressure large institutional shareholders well proxy advisory firm institutional shareholder services iss suggesting deal rejected lilly increased offer billion per share resistance voiced large shareholders iss advised shareholders accepting new offer still deemed january special meeting shareholders voted support eli lilly closed transaction acquire icos billion january result acquisition eli lilly gained complete ownership cialis promptly shut icos operations laid icos personnel except employees working biologics icos largest biotechnology company state washington time acquisition employed around december cmc biopharmaceuticals copenhagenbased provider contract biomanufacturing services bought bothell biologics facility retained existing addition layoff icos employees aspects acquisition equally controversial assertions icos sold cheaply conflicts interest latter related icos senior executives despite poor stock performance part failed clinical development programs inability successfully license drugs preceding years massively compensated upon successful senior executives icos received cash payments worth combined million selling company eli icos chairman chief executive president paul clark received golden parachute worth million severance pay cashedout stock options restricted stock awards bonuses retention closing nine senior icos executives received similar packages worth httpsenwikipediaorgwikiicos